Preeclampsia
Conditions
Keywords
Preeclampsia, apheresis, sflt-1
Brief summary
The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1
Detailed description
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) : * Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP * Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP * Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP * Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP * Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP
Interventions
BIOLOGICALA collection of maternal plasma and serum
A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
Sponsors
Assistance Publique - Hôpitaux de Paris
INSERM UMR-S 1139
URC-CIC Paris Descartes Necker Cochin
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 50 years old * Singleton pregnancies between 20 and 41 weeks of gestation * Preeclampsia * Normal pregnancy
Exclusion criteria
* Age\<18 * Infectious disease: HIV, HBV or HCV * Multiple pregnancies * Opposition of the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ratio sFlt-1/PlGF | Day 0 | measurement of of sFlT-1 and PlGF |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kinetics of these ratios sFlt-1/PlGF during pregnancy | until 5 month | measurement of of sFlT-1 and PlGF at many times |
Countries
France
Contacts
STUDY_DIRECTOREdouard Lecarpentier, MD, PhD
Centre Hospitalier intercommunal de Créteil
Outcome results
None listed